Information de reference pour ce titreAccession Number: | 00000658-201107000-00022.
|
Author: | Merkow, Ryan P. MD *,+,++; Bilimoria, Karl Y. MD, MS *,++; McCarter, Martin D. MD +; Cohen, Mark E. PhD ++; Barnett, Carlton C. MD +; Raval, Mehul V. MD, MS *,++; Caprini, Joseph A. MD, MS [P]; Gordon, Howard S. MD [S]; Ko, Clifford Y. MD, MS, MSHS ++,[sharp]; Bentrem, David J. MD, MS *
|
Institution: | (*)Department of Surgery, Jesse Brown VAMC, Northwestern University, Feinberg School of Medicine, Chicago, IL. (+)Department of Surgery, University of Colorado Denver School of Medicine, Aurora, CO. (++)Division of Research and Optimal Patient Care, American College of Surgeons, Chicago, IL. ([S])Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL ([P])Department of Medicine, Jesse Brown VAMC, University of Illinois at Chicago, Chicago, IL (#)Department of Surgery, University of California, Los Angeles (UCLA) and VA greater Los Angeles Healthcare System, Los Angeles, CA.
|
Title: | |
Source: | Annals of Surgery. 254(1):131-137, July 2011.
|
Abstract: | Objective: To (1) define the frequency of overall and postdischarge venous thromboembolism (VTE) after cancer surgery, (2) identify VTE risk for individual cancer operations, and (3) assess mortality rates in patients who experienced a VTE.
Summary and Background Data: Cancer is a known risk factor for VTE but less is known about VTE risk after specific cancer operations. Moreover, most cancer patients routinely receive VTE prophylaxis postoperatively while in the hospital, but few receive prolonged prophylaxis despite strong evidence it reduces postdischarge events.
Methods: From 211 ACS NSQIP hospitals, 44,656 patients undergoing surgery for 9 cancers were identified (2006-2008). The frequency of VTE within 30-days of surgery was evaluated by cancer site and categorized as occurring before or after discharge. Multivariable logistic regression models were constructed to assess risk factors associated with VTE.
Results: VTE occurred in 1.6% of all patients, most frequently after esophagogastric (4.2%) and hepatopancreaticobiliary (3.6%) surgery. Overall, 33.4% of VTEs occurred postdischarge (from 17.9% for esophagogastric to 100% for endocrine operations). Factors associated with VTE were age (>=65 years), cancer/procedure type, metastatic disease, congestive heart failure, body mass index (BMI; >=25 kg/m2), ascites, thrombocytosis (>400,000 cells/mm3), albumin (<3.0 g/dL), and operation duration (>2 hours; all P < 0.001). Overall VTE was significantly more likely after gastrointestinal, lung, prostate, and ovarian/uterine operations (all P < 0.001). In those experiencing a VTE, mortality increased over 6-fold (8.0% vs. 1.3%; P < 0.001).
Conclusion: One-third of VTE events in cancer surgery patients occurred postdischarge. Postoperative VTE was associated with operation type. Routine postdischarge VTE prophylaxis should be considered for high-risk patients.
(C) 2011 Lippincott Williams & Wilkins, Inc.
|
References: | 1. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653-1661.
2. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.
4. Kakkar AK, Haas S, Wolf H, et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005;94(4):867-871.
5. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980.
6. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4(11):2384-2390.
7. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007;45(2):335-341; discussion 341-342.
8. Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thromb Res. 2009;123(Suppl 4):S30-S34.
9. Rodrigues CA, Ferrarotto R, Kalil Filho R, et al. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis. 2010;30:67-78.
10. American College of Surgeons - National Surgical Quality Improvement Program. Available at www.facs.org/acsnsqip.html. Accessed March 1, 2010.
11. Khuri SF, Henderson WG, Daley J, et al. Successful implementation of the Department of Veterans Affairs' National Surgical Quality Improvement Program in the private sector: the Patient Safety in Surgery study. Ann Surg. 2008;248(2):329-336.
12. Hall BL, Hamilton BH, Richards K, et al. Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals. Ann Surg. 2009;250(3):363-376.
13. Shiloach M, Frencher SK Jr, Steeger JE, et al. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 2010;210(1):6-16.
14. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919-4926.
15. Quality Net, Surgical Care Improvement Project (SCIP) Project Information. Available at www.qualitynet.org. Accessed June 30, 2010.
16. National Quality Forum. Available at www.qualityforum.org. Accessed June 30, 2010.
17. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
18. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.
19. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2009(1):CD004318. DOI:10.1002/14651858.CD004318.pub2.
20. Byrne M, Reynolds JV, O'Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer. 102(1):73-79.
21. Bottaro FJ, Elizondo MC, Doti C, et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost. 2008;99(6):1104-1111.
22. Kakkar AK. Prevention of venous thromboembolism in the cancer surgical patient. J Clin Oncol. 2009;27(29):4881-4884.
23. Bradley CT, Brasel KJ, Miller JJ, et al. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery. Ann Surg Oncol. 2010;17(1):31-39.
24. Mukherjee D, Lidor AO, Chu KM, et al. Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surg. 2008;12(11):2015-2022.
25. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992;127(3):310-313.
26. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505.
27. Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008;15(12):3567-3578.
28. Paneesha S, McManus A, Arya R, et al. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost. 2010;103(2):338-343.
29. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2(12):2156-2161.
30. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829.
31. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 8(1):114-120.
32. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 102(Suppl 1):S2-S9.
33. Shiloach M, Frencher SK Jr, Steeger JE, et al.., Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 210(1):6-16.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine. Health Professions.
|
ISSN: | 0003-4932
|
NLM Journal Code: | 67s, 0372354
|
DOI Number: | https://dx.doi.org/10.1097/SLA.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|